These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
134 related articles for article (PubMed ID: 12487509)
1. Improved haemoglobin concentrations with IV darbepoetin alfa--case studies of haemodialysis patients. Thiele A; Wittner M Curr Med Res Opin; 2002; 18(7):440-4. PubMed ID: 12487509 [TBL] [Abstract][Full Text] [Related]
2. Treatment of anaemia in dialysis patients with unit dosing of darbepoetin alfa at a reduced dose frequency relative to recombinant human erythropoietin (rHuEpo). Locatelli F; Canaud B; Giacardy F; Martin-Malo A; Baker N; Wilson J Nephrol Dial Transplant; 2003 Feb; 18(2):362-9. PubMed ID: 12543893 [TBL] [Abstract][Full Text] [Related]
3. Correction of anaemia with darbepoetin alfa in patients with chronic kidney disease receiving dialysis. Macdougall IC; Matcham J; Gray SJ; Nephrol Dial Transplant; 2003 Mar; 18(3):576-81. PubMed ID: 12584282 [TBL] [Abstract][Full Text] [Related]
4. [Multicenter study of darbepoetin alfa in the treatment of anemia secondary to chronic renal insufficiency on dialysis]. Martínez Castelao A; Reyes A; Valdés F; Otero A; López de Novales E; Pallardó L; Tabernero JM; Hernández Jaras J; Lladós F Nefrologia; 2003; 23(2):114-24. PubMed ID: 12778875 [TBL] [Abstract][Full Text] [Related]
5. Darbepoetin alfa effectively maintains haemoglobin concentrations at extended dose intervals relative to intravenous or subcutaneous recombinant human erythropoietin in dialysis patients. Brunkhorst R; Bommer J; Braun J; Haag-Weber M; Gill C; Wagner J; Wagener T; Nephrol Dial Transplant; 2004 May; 19(5):1224-30. PubMed ID: 14993489 [TBL] [Abstract][Full Text] [Related]
6. Australian haemodialysis patients on intravenous epoetin alfa or intravenous darbepoetin alfa: how do they compare? Pussell BA; Walker R; Nephrology (Carlton); 2007 Apr; 12(2):126-9. PubMed ID: 17371333 [TBL] [Abstract][Full Text] [Related]
7. [Treatment of renal anemia with darbepoetin alfa: results of an Austrian multicenter study]. Hörl WH; Holzer H; Mayer GJ; Wien Klin Wochenschr; 2002 Dec; 114(23-24):967-71. PubMed ID: 12635463 [TBL] [Abstract][Full Text] [Related]
8. [Advances in therapy of renal anemia: darbepoetin alfa]. Schaefer R Wien Klin Wochenschr; 2002 Dec; 114(23-24):955-7. PubMed ID: 12635460 [No Abstract] [Full Text] [Related]
9. A comparison of haemoglobin levels and doses in haemodialysis patients treated with subcutaneous or intravenous darbepoetin alfa: a German prospective, randomized, multicentre study. Bommer J; Asmus G; Wenning M; Bommer G Nephrol Dial Transplant; 2008 Dec; 23(12):4002-8. PubMed ID: 18676350 [TBL] [Abstract][Full Text] [Related]
10. [Darbepoetin-alfa treatment of anemia secondary to chronic renal failure in dialysis patients: Results of a French multicenter study]. Kessler M; Hannedouche T; Fitte H; Cayotte JL; Urena P; Réglier JC; Nephrol Ther; 2006 Sep; 2(4):191-9. PubMed ID: 16966064 [TBL] [Abstract][Full Text] [Related]
11. Randomized study of darbepoetin alfa and recombinant human erythropoietin for treatment of renal anemia in chronic renal failure patients receiving peritoneal dialysis. Li WY; Chu TS; Huang JW; Wu MS; Wu KD J Formos Med Assoc; 2008 Nov; 107(11):843-50. PubMed ID: 18971153 [TBL] [Abstract][Full Text] [Related]
12. Darbepoetin alfa administered every other week maintains hemoglobin levels over 52 weeks in patients with chronic kidney disease converting from once-weekly recombinant human erythropoietin: results from simplify the treatment of anemia with Aranesp (STAAR). Hertel J; Locay H; Scarlata D; Jackson L; Prathikanti R; Audhya P Am J Nephrol; 2006; 26(2):149-56. PubMed ID: 16636531 [TBL] [Abstract][Full Text] [Related]
13. Practical guidelines for the use of NESP in treating renal anaemia. Aljama P; Bommer J; Canaud B; Carrera F; Eckardt KU; Hörl WH; Krediet RT; Locatelli F; Macdougall IC; Wikström B; Nephrol Dial Transplant; 2001; 16 Suppl 3():22-8. PubMed ID: 11402087 [No Abstract] [Full Text] [Related]
14. [Feasibility strategy of darbepoetin alfa administration every other week: 2005-2007 experience in a dialysis unit]. Rottembourg JB; Dansaert A Nephrol Ther; 2011 Dec; 7(7):549-57. PubMed ID: 21622039 [TBL] [Abstract][Full Text] [Related]
15. Randomized trial of darbepoetin alfa for treatment of renal anemia at a reduced dose frequency compared with rHuEPO in dialysis patients. Vanrenterghem Y; Bárány P; Mann JF; Kerr PG; Wilson J; Baker NF; Gray SJ; Kidney Int; 2002 Dec; 62(6):2167-75. PubMed ID: 12427142 [TBL] [Abstract][Full Text] [Related]
16. Clinical implications of converting stable haemodialysis patients from subcutaneous to intravenous administration of darbepoetin alfa. Aarup M; Bryndum J; Dieperink H; Joffe P Nephrol Dial Transplant; 2006 May; 21(5):1312-6. PubMed ID: 16396971 [TBL] [Abstract][Full Text] [Related]
17. Treatment of anemia with darbepoetin alfa administered de novo once every other week in chronic kidney disease. Suranyi MG; Lindberg JS; Navarro J; Elias C; Brenner RM; Walker R Am J Nephrol; 2003; 23(2):106-11. PubMed ID: 12481149 [TBL] [Abstract][Full Text] [Related]
18. A trial of subcutaneous administration of darbepoetin alfa once every other week for the treatment of anemia in peritoneal dialysis patients. Mahajan S; Boulton H; Gokal R J Nephrol; 2004; 17(5):687-92. PubMed ID: 15593036 [TBL] [Abstract][Full Text] [Related]
19. The efficacy of intravenous darbepoetin alfa administered once every 2 weeks in chronic kidney disease patients on haemodialysis. Carrera F; Oliveira L; Maia P; Mendes T; Ferreira C Nephrol Dial Transplant; 2006 Oct; 21(10):2846-50. PubMed ID: 16891642 [TBL] [Abstract][Full Text] [Related]
20. Darbepoetin alfa once every 2 weeks for treatment of anemia in dialysis patients: a combined analysis of eight multicenter trials. Mann J; Kessler M; Villa G; Martinez-Castelao A; Feldt-Rasmussen B; Cruz J; Hörl WH; Mattin C; Praml C; Wilkie M Clin Nephrol; 2007 Mar; 67(3):140-8. PubMed ID: 17390738 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]